# An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System

## TL;DR

This study identifies 30 drugs most commonly linked to pulmonary embolism using FDA adverse event data, highlighting risks for cancer and immune disease treatments.

## Contribution

The study provides a novel ranking of 30 drugs most strongly associated with pulmonary embolism using FDA adverse event data.

## Key findings

- TESTIM, BARICITINIB, and NUVARIANG showed the strongest association with pulmonary embolism (PE).
- Most of the top 30 drugs are biologics and immunomodulators.
- The findings suggest a need for caution when using these drugs due to PE risk.

## Abstract

Pulmonary embolism (PE) is a common disease and a common cause of death. However, it is currently unclear which clinically common drugs can lead to PE.

We collected, organized, and analyzed reports from the first quarter of 2018 to the fourth quarter of 2022. We performed disproportionality analysis algorithms to calculate reporting odds ratio (ROR), which could quantify the signal values of different adverse events (AEs).

We have screened a total of 3091 drugs, with AE containing “PE” and calculated the ROR signal values of the top 30 drugs reported and ranked them. TESTIM (ROR = 32.03[28.77–35.66]), BARICITINIB (ROR = 23.48[20.55–26.83]), and NUVARIANG (ROR = 19.89[17.13–23.10]) are the drugs with the strongest correlation with PE. In addition, among the 30 drugs with the strongest correlation with PE, most of which are Biologics & Immunomodulators. Therefore, when using these 30 drugs, it is necessary to be alert to the possible risk of PE.

In our study, we filtered 30 common drugs that could cause PE through the FAERS public database, which provides theoretical support for drug selection in the treatment of malignant tumors and IMID.